Search Results - "Mestres, Joan Albanell"

Refine Results
  1. 1
  2. 2

    Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer by Tusquets Trías de Bes, Ignasi, Servitja Tormo, Sònia, Albanell Mestres, Joan

    Published in Biomedicine & pharmacotherapy (01-01-2009)
    “…Abstract Women are at considerable risk of recurrence in the first few years following initial treatment for early breast cancer. To reduce the risk of…”
    Get full text
    Journal Article
  3. 3

    Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations by Tamborero, David, Rubio-Perez, Carlota, Deu-Pons, Jordi, Schroeder, Michael P, Vivancos, Ana, Rovira, Ana, Tusquets, Ignasi, Albanell, Joan, Rodon, Jordi, Tabernero, Josep, de Torres, Carmen, Dienstmann, Rodrigo, Gonzalez-Perez, Abel, Lopez-Bigas, Nuria

    Published in Genome medicine (28-03-2018)
    “…While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7

    The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene by Tormo, Eduardo, Adam-Artigues, Anna, Ballester, Sandra, Pineda, Begoña, Zazo, Sandra, González-Alonso, Paula, Albanell, Joan, Rovira, Ana, Rojo, Federico, Lluch, Ana, Eroles, Pilar

    Published in Scientific reports (25-01-2017)
    “…A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy by Muntasell, Aura, Cabo, Mariona, Servitja, Sonia, Tusquets, Ignasi, Martínez-García, María, Rovira, Ana, Rojo, Federico, Albanell, Joan, López-Botet, Miguel

    Published in Frontiers in immunology (13-11-2017)
    “…Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology by Colomer, R., Aranda-López, I., Albanell, J., García-Caballero, T., Ciruelos, E., López-García, M. Á., Cortés, J., Rojo, F., Martín, M., Palacios-Calvo, J.

    Published in Clinical & translational oncology (01-07-2018)
    “…This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14

    Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells by López-Arribillaga, Erika, Rodilla, Verónica, Colomer, Carlota, Vert, Anna, Shelton, Amy, Cheng, Jason H., Yan, Bing, Gonzalez-Perez, Abel, Junttila, Melissa R., Iglesias, Mar, Torres, Ferran, Albanell, Joan, Villanueva, Alberto, Bigas, Anna, Siebel, Christian W., Espinosa, LLuís

    Published in Nature communications (31-07-2018)
    “…Delta ligands regulate Notch signaling in normal intestinal stem cells, while Jagged1 activates Notch in intestinal adenomas carrying active β-catenin. We used…”
    Get full text
    Journal Article
  15. 15
  16. 16

    MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC) by Casadevall, David, Gimeno, Javier, Clavé, Sergi, Taus, Álvaro, Pijuan, Lara, Arumí, Miriam, Lorenzo, Marta, Menéndez, Silvia, Cañadas, Israel, Albanell, Joan, Serrano, Sergio, Espinet, Blanca, Salido, Marta, Arriola, Edurne

    Published in Oncotarget (30-06-2015)
    “…We aimed to assess MET intratumoral heterogeneity and its potential impact on biomarker-based patient selection as well as potential surrogate biomarkers of…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19
  20. 20